Recursion Pharmaceuticals, Inc. ( RXRX) Stock. Should you Buy or Sell? $ 13.27
0.44 (3.21 %)
Recursion Pharmaceuticals, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$1.03 M|
|Market Cap||$2.3 B|
|52 Week Range||$4.92 - $29.36|
Recursion Pharmaceuticals, Inc. opened the day at $13.27 which is +'3.21 % on yesterday's close. Recursion Pharmaceuticals, Inc. has a 52 week high of $29.36 and 52 week low of $4.92, which is a difference of $24.44. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $2.3 B and total net profit is $10178000 which means the company is trading at 225.66 times profit to market capitalization. Theoretically, if you were to buy Recursion Pharmaceuticals, Inc. for $2.3 B, it would take 15 years to get your money back. Recursion Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Recursion Pharmaceuticals, Inc. Stock Forecast - Is Recursion Pharmaceuticals, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-18.052|
Valuing Recursion Pharmaceuticals, Inc.
|Price Book Value Ratio||5.223||Price To Book Ratio||5.223|
|Price To Sales Ratio||176.372||Price Earnings Ratio||-9.770|
How liquid is Recursion Pharmaceuticals, Inc.
|Debt Ratio||0.349||Debt Equity Ratio||0.537|
|Long Term Debt To Capitalization||0.099||Total Debt To Capitalization||0.109|
Latest news about Recursion Pharmaceuticals, Inc.
Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.
SALT LAKE CITY , Sept. 1, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Morgan Stanley Global Healthcare Conference — September 12 through September 14, 2022 Goldman Sachs Global Sustainability Forum — September 29, 2022 About Recursion Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology.
Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.
Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.